cyrilzakka/clinical-trials huggingface dataset:
The Impact of Alternative Social Assistance Disbursement on Drug-related Harm

This study evaluates whether altering the timing and frequency of social assistance disbursement reduces drug related-harms that increase on the days surrounding monthly synchronized government social assistance cheque issue.

Coordinated monthly income assistance payments, while seeking to alleviate poverty, can also have negative and unintended impacts, particularly among people who use illicit drugs (PWUD). Observational research has identified escalations in drug-related harm coinciding with monthly assistance payments, such as overdose, treatment interruption, hospital admissions and public disorder. This project varies the timing and frequency of income assistance disbursement, and evaluates whether varying income assistance disbursement reduces drug-related harm coinciding with coordinated income assistance.

Conducted among 273 PWUD, participants will be allocated for 6 income assistance cycles to a control or one of two intervention arms. Participants in the control arm will receive payments according to the existing monthly government schedule. Participants in the intervention arm will receive their income assistance: (1) monthly on a day different from government cheque issue; or (2) semi-monthly on days different from government cheque issue. The intervention will be evaluated using qualitative and quantitative methods for its impact on drug use and related harms.

Eligibility Criteria:
Inclusion Criteria:

* be ≥19 years of age or older
* reside in greater Vancouver, Canada
* report regular use of illicit drugs other than cannabis
* receive monthly provincial income assistance
* are not currently administered (where cheque issue/money is externally managed)
* be eligible and willing to be a client of the local credit union who will administer the intervention
* report intensified drug use around government cheque issue days
* provide written informed consent
* be willing to comply with study procedures

Exclusion Criteria:

* plan to relocate outside Vancouver
* have plans to discontinue income assistance
Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults

A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of QL1206 and Prolia® in healthy adults

This is a phase I,single center, randomized, double-blind and parallel group clinical trial . The primary objective is to assess the pharmacokinetic similarity of single and subcutaneous injections of QL1206 or Prolia® in healthy volunteers. The secondary objective are to assess the Clinical safety and immunogenicity similarity of single and subcutaneous injections of QL1206 or Prolia® in healthy volunteers. Meanwhile，observing the pharmacodynamic similarities of QL1206 or Prolia® preliminarily. Subjects would receive a single 60mg（1ml） of QL1206 or through subcutaneous injection.

Eligibility Criteria:
Inclusion Criteria:

* Sign the informed consent form and fully understand the test content, process and possible adverse reactions, and be able to complete the study according to the test plan requirements;
* Aged ≥18 years or ≤50 years, male or female (including the boundary value);
* Agree to take effective contraceptive measures throughout the study period (including not limited to: hormonal drugs of pregnancy, physical contraception, surgery, abstinence, etc., until at least 6 months after the last study is administered;
* Clinical laboratory examination, chest X-ray, abdominal B-ultrasound, electrocardiogram, physical examination, vital signs and various examinations are normal or abnormal without clinical significance

Exclusion Criteria:

* Occurred or suffering from osteomyelitis or ONJ (mandibular necrosis) previously.
* Serum calcium levels are outside the normal range of the laboratory, or the subject uses calcium supplements in the screening period.
* The dental or jaw disease that is active, requiring oral surgery; or planned for invasive dental surgery during the study; or dental or oral surgery wounds have not healed;
* Subject has viral hepatitis (including hepatitis B and hepatitis C), AIDS antibodies, and Treponema pallidum antibodies;
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of treatment naive advanced esophageal squamous cell carcinoma patients. The purpose of this study was to evaluate the efficacy and safety of immunotherapy combined with chemotherapy and residual lesions irradiation of esophageal squamous cell carcinoma.


Eligibility Criteria:
Inclusion Criteria:

1. Diagnosed with Stage IV esophagus squamous cell carcinoma.
2. Expected survival time ≥3 months
3. Enrolled patients must have at least one measurable lesion conforming to the RECIST V1.1 definition.
4. Physical fitness ECOG score of 0 or 1
5. Organ function levels must meet the following requirements and meet the following standards:

A) Bone marrow function: absolute neutrophil count (ANC) ≥1.5×10\^9/L, platelet count ≥90×10\^9/L, hemoglobin ≥90 g/L; B) Liver function: Total bilirubin TBIL≤1.5×ULN (total bilirubin ≤3×ULN in Subjects with Gilbert's syndrome, liver cancer or liver metastasis), AST and ALT ≤2.5×ULN in patients without liver metastasis, AST and ALT ≤5.0×ULN in patients with liver metastasis; C) Renal function: Creatinine (Cr) ≤1.5×ULN, or creatinine clearance (Ccr) ≥50 mL/min (according to Cockcroft and Gault formula); D) Urine routine / 24-hour protein quantification: qualitative urine protein ≤1+ (if qualitative urine protein ≥2+, 24 hours \< 1g can be included); E) Cardiac function: left ventricular ejection fraction ≥50%; F) Coagulation function: International standardized ratio (INR) ≤1.5×ULN, and activated partial thrombin time (APTT) ≤1.5×ULN;

Exclusion Criteria:

1. Known or suspected history of active autoimmune diseases, autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes)
2. Have a history of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency disease, or history of organ transplantation and bone marrow transplantation；Interstitial lung disease, drug-induced pneumonia,requiring steroid therapy or active pneumonia with clinical symptoms or severe pulmonary dysfunction；
3. There are clinical symptoms or diseases of the heart that are not well controlled, such as: (1) heart failure of NYHA class 2 or higher (2) unstable angina (3) myocardial infarction within 24 weeks (4) clinical need for treatment or Interventional supraventricular or ventricular arrhythmia；
4. Have a tendency to hereditary bleeding or coagulopathy. Clinically significant bleeding symptoms or clear bleeding tendency within 3 months prior to enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood++ and above；
5. Allergic reactions to test drugs for this application；
6. Pregnant or lactating women； Those whom the investigator considered unsuitable for inclusion。
Montelukast for Treatment of Uremic Pruritus

In this study hemodialysis patients that underwent dialysis thrice weekly screen for uremic pruritus and 80 patients that at least have refractive pruritus that lead to sleep and daily activity disorders enroll in this study. These patients should have at least a course of therapy without proper response. After proper informing patients and taking testimonial patients enter to study. Then patients randomized in case and control group. In case group, patients took montelukast 10 milligram daily and in control group took placebo for 30 days. Other antipruritic or antiinflammatory medication has been stopped one week prior to starting treatment. Calcium, phosphorous, urea, creatinine, highly sensitive CRP (hsCRP), Parathyroid Hormone (PTH), hemoglobin and kt/V were measured at beginning and at end of study. pruritus severity assessed by Detailed Pruritus Score that introduced by Duo and Visual Analogue Score in beginning and at end of study in both group. Sleep disorder score and its severity added to crude score at beginning and end of study and change of measures analyzed.

Montelukast is an antileukotrien receptor antagonist that seems to be effective as an antipruritic medication via blocking inflammatory pathways.

Eligibility Criteria:
Inclusion Criteria:

* hemodialysis patients that refered to dialysis centers and at least on hemodialysis thrice weekly
* presence of uremic pruritus
* patients that at least had refractive pruritus that lead to sleep disorders or compromised daily activities
* patients should took a course of antipruritic treatment with no proper response

Exclusion Criteria:

* presence of pruritus less than three months
* kt/V less than 1.2
* presence of pruritus due to other cause other than uremic state
* presence of other pruritic diseases; malignancies; cholestasis; hepatitis B and C infection
* treatment with corticosteroid
* presence of anemia with hemoglobin less than 10
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis

The study consist of a retrospective analysis of the etiologies, investigations and outcomes of patients presenting between 2005 to 2010 with hemoptysis in a North-American Tertiary center.

RATIONALE:

Hemoptysis, mild or massive, is worrisome for both patients and physicians. The management is different depending on the causes, which are not well defined for the North American population. Despite the fact that this symptom is commonly reported in clinic, there are only a few studies published on this subject in the North-American population. Tuberculosis was a frequent cause of hemoptysis described in populations overseas, which seems less prevalent in the investigators center.

Also, there are no known official guidelines regarding the investigation and management of hemoptysis. The investigators hypothesized that the use of modern technology in a North American population may result in different findings and provide a more accurate diagnostic approach.

Therefore, the study compares the different etiologies of hemoptysis and investigation modalities used in patients presenting in a North-American tertiary center.

METHOD:

The investigators did a retrospective analysis of medical chart from patients with hemoptysis who visited the investigators center between 2005 and 2010. Each visit has been reviewed individually to describe the characteristics of patients, etiologies of hemoptysis and investigation modalities used. All-cause mortality at 2 years was also recorded.

Descriptive statistical analyses will conducted on the data available.

Eligibility Criteria:
Inclusion Criteria:

Any patient over the age of 18 presenting with:

* A diagnosis of hemoptysis on an outpatient basis.
* A diagnosis of hemoptysis during consultation in the emergency department.
* A diagnosis of hemoptysis on the admission sheet.
* A diagnosis of hemoptysis when hospitalized.
* A complication of hemoptysis
* Hemoptysis on the report of the bronchoscopy, chest computed tomography, pulmonary angiography, ventilation-perfusion single-photon emission computed tomography or blood transfusion.

Exclusion Criteria:

* Patients under 18 years of age.
* Patient who refused investigation for hemoptysis.
* Incomplete medical chart
Telehealth Mindfulness-Based Music and Songwriting for Parents of Children With Intellectual/Developmental Disabilities

This is a pilot study of the feasibility and potential impact of a Mindfulness-Based Music and Songwriting program (delivered via telehealth) on stress and well-being in parents/caregivers of children with intellectual or developmental disabilities. Participants are randomized to participate in the mindfulness program or a business-as-usual control group.

This is a pilot study of the feasibility and potential impact of a Mindfulness-Based Music and Songwriting program (delivered via telehealth) on stress and well-being in parents/caregivers of children with intellectual or developmental disabilities. Participants are randomized to participate in the mindfulness program or a business-as-usual control group.

During mindfulness sessions, parents/caregivers are supported by a therapist to learn and apply mindfulness practices through music-based meditations and songwriting. Participants write two songs during the program. Parents complete surveys throughout the program.

Eligibility Criteria:
Inclusion Criteria:

* Parent/caregiver of a child with an intellectual or developmental disability
* Parent speaks and reads fluent English
* Able to attend weekly telehealth/virtual sessions

Exclusion Criteria:

-
Characterize Tumor Hypoxia by Magnetic Resonance Imaging

The purpose of this research study is to measure the hypoxia (low oxygen condition) in prostate cancers and its effect in survival. In this study, investigators will assess hypoxia by magnetic resonance imaging (MRI) and create a hypoxia score. Investigators will study the hypoxia score and how it correlates (if any) to the disease aggressiveness as well as its effect on the treatment outcomes.

Primary Objective(s):

* To assess hypoxia in primary prostate tumors by magnetic resonance imaging.
* To correlate hypoxic score with disease aggressiveness (proliferation biomarkers' expression).

Secondary Objective(s):

* To correlate hypoxic score with ExoHypoxic concentration in plasma of same patient.
* To correlate hypoxic score with fatty acid synthase (FASN) expression.

Eligibility Criteria:
Inclusion Criteria:

* The minimum age for this study is men 40 years and older. Prostate cancer mainly affects men over the age of 40.
* Patients with Caucasian and African American race
* Patients with pathology-proven prostate cancer (Gleason 6 or higher)
* Patients who have not yet undergone therapy (systemic drugs, radiation, or prostatectomy)
* Patients who will have a radical prostatectomy as standard of care.
* Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).

Exclusion Criteria:

* Patients who have already received some form of treatment or are not planning to undergo radical prostatectomy for treatment.
* Patients with any other cancer along with prostate cancer.
* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)

The investigators studied the effects of adenosine on the reconnection rate after successful pulmonary veins isolation by radiofrequency catheter ablation in patients with drug-resistant atrial fibrillation

Pulmonary vein isolation has emerged as an effective therapy for paroxysmal atrial fibrillation. However, atrial fibrillation recurs in up to 50% of patients, generally because of recovery of pulmonary vein conduction.

Adenosine given during the initial procedure may reveal dormant pulmonary vein conduction, thereby identifying the need for additional ablation, leading to improved outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed atrial fibrillation
* recurrence of symptomatic atrial fibrillation in spite of Antiarrhythmic drug use
* written informed consent

Exclusion Criteria:

* intracardiac thrombus
* pregnancy
Efficacy of VR Based Sword Fighting Exercises to Improve Upper Body Movements in Hemiplegic Patients

this thesis endeavors to shed light on the efficacy of VR-based sword-fighting exercises as a rehabilitation tool for improving upper body movement in hemiplegic patients.

By amalgamating clinical insights, technological advancements, and theoretical frameworks, this research aims to contribute to the growing body of knowledge in neurorehabilitation and pave the way for innovative, effective, and engaging interventions to enhance the lives of individuals affected by hemiplegia.

Eligibility Criteria:
Inclusion Criteria:

* Age 21-80 years
* First clinical stroke, ischemic or hemorrhagic, with diagnosis of stroke confirmed on CT/MRI brain scan.
* Less than 6 weeks after stroke onset
* Upper limb weakness of Medical Research Council (MRC) motor power of grade 2-4 motor power in either the shoulder, elbow or the fingers of the hemiplegic upper extremity
* Subject can understand simple instructions and learn

Exclusion Criteria:

* Recurrent stroke
* History of epilepsy
* Presence of arthritis or pain in the affected upper limb restricting repetitive exercises
* Severe aphasia or cognitive impairment, or other psychiatric illnesses that limit the ability to participate or give consent.
Online Versus Real Time Dental Education

Through covid period the concept of distant, online and hybrid learning evolved in reaction to lockdown. This hindered the capability of students to receive and practice on patients as they should do. The current study compared data of two classes that had different education systems because of COVID-19. Class 2020 had nearly a complete online teaching of theoretical part, practical and minimal patient interaction. Class 2021 had the opportunity to try both systems because of partial lockdown in 2020 and complete return to work in 2021.

Methodology

Evaluation of the quality of teaching of oral surgery curriculum during the COVID 19 lock down.

The Objective Achieving high quality teaching in similar future situations. The Standards used for evaluation. The course report published by the faculty student's affair section and the students survey.

ETHICS \& ENGAGEMENT This data was collected from the course report published by the faculty student's affair section. All students shared in the survey consented that their data can be used and presented for research and audit purposes. All adjunctive research presented in this audit got ethical clearance from the Faculty Ethical Committee.

sample Fourth year students studying oral surgery had online teaching and forty students had real time teaching.

Survey Questions A short five-question survey was used to assess the students overall and was given to 40 students from each class to assess the student's satisfaction with the quality of the education.

The survey questions:

1. Technical skills taught during the academic year were valuable or not.
2. real patients provide higher skills compared to dummies and models
3. Teaching in real classroom is better than teaching through online portal
4. do you prefer introudction of dummies before real time patients
5. Regarding the overall satisfaction by the education system The survey portal had a percentage satisfactory meter. Responses over 50% or equal 50% were considered yes and responses below 50% were considered no.

Statistical assessment:

Chi-square test was used to assess the statistical significance between the results using SPSS software.

Eligibility Criteria:
Inclusion Criteria:

* fourth year students attending normally in ain shams university

Exclusion Criteria:

* any student who is repeating or had this course before
Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

To compare the bioavailability and pharmacokinetic profiles of two different formulations MN-166 50mg, extended release (ER) tablets with MN-166 10mg capsules in a single-dose regimen in healthy volunteers

Part 1:

To compare the bioavailability and pharmacokinetic profiles of two different formulations MN-166 50mg, extended release (ER) tablets with MN-166 10mg capsules in a single-dose regimen in healthy volunteers; and To choose one of the two MN-166 50mg ER tablet formulations for evaluation in Part 2.

Secondary: To determine the safety and tolerability of the two formulations of MN-166 ER tablets in a single-dose regimen in healthy volunteers.

Part 2:

To compare the bioavailability and steady-state pharmacokinetic profile of MN-166 50mg ER tablet with MN-166 10mg capsules in a multiple-dose regimen in healthy volunteers; and

Secondary: To determine the safety and tolerability of MN-166 ER tablets in a multiple-dose regimen in healthy volunteers

Eligibility Criteria:
Inclusion Criteria:

1. Able to provide written informed consent.
2. Healthy non-smoking male and female subjects aged 18 to 65 years, inclusive.
3. No clinical abnormalities in laboratory and urine analyses.
4. Normal renal function (GFR \> 90mL/min).
5. Liver enzymes should be less than twice the upper limit of normal (ULN).
6. Screening electrocardiogram (ECG) with QT interval adjusted for heart rate within normal limits.
7. Agree to use barrier contraceptive methods during the course of the study (hormonal contraceptive alone is not acceptable).
8. Females of child-bearing potential must have a negative pregnancy test on Study Day 1.

Exclusion Criteria:

1. Known hypersensitivity to Pinatos® or its components.
2. Condition(s) which might affect drug absorption, metabolism or excretion.
3. Untreated mental illness, current drug addiction or abuse or alcoholism.
4. Donated blood in the past 90 days or have poor peripheral venous access.
5. Platelets \< l00,000/mm3, history of thrombocytopenia.
6. Confirmed diagnosis of chronic liver disease, e.g., chronic Hep. B, Hep. C infection, auto-immune, alcoholic or neoplastic liver disease.
7. Positive serostatus for HIV.
8. Currently pregnant or nursing.
9. History of clinically significant cardiovascular, pulmonary, endocrine, neurological, metabolic, or psychiatric diseases.
10. Received an investigational drug in the past 30 days.
11. Unable to swallow tablets.
The Effect of Blood Transfusion on Endothelial Function

Blood transfusion is often used to treat patients with Anemia. The period of storage of blood products prior to use for transfusion may vary. Prolonged storage of blood products may result in changing their biochemistry.

This study aims to look into whether the transfusion of "old" blood, which is stored for more than 7 days, as compared to the transfusion of "Fresh" blood, which is stored for less than 7 days, will affect endothelial function.

Endothelial function assessed pre and post transfusion. The EndoPAT uses a unique bio-sensors that are placed on the fingertips to measure pressure. The test takes about 20-25 minutes. During the procedure the participant will have biosensors placed on the index finger of each hand. The nondominant arm will have a blood pressure cuff applied with sufficient pressure for five minutes. At the end of the test the device will provide a reading that assesses the level of endothelial function/dysfunction.

Eligibility Criteria:
Inclusion Criteria:

* Age is \> 18 years
* Need recurrent blood transfusion

Exclusion Criteria:

* Latex Allergy
* Life expectancy is less than 6 months
* History or evidence of drug or alcohol abuse in the last 12 months
* Any medical condition that will place the participant at a higher risk if they participate in the study